The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance.
BACKGROUND:Meta-analyses on impact of isoniazid-resistant tuberculosis informed the World Health Organization recommendation of a levofloxacin-strengthened rifampicin-based regimen. We estimated the effect of initial rifampicin resistance (Rr) and/or isoniazid resistance (Hr) on treatment failure or...
Main Authors: | Armand Van Deun, Tom Decroo, Aung Kya Jai Maug, Mohamed Anwar Hossain, Murid Gumusboga, Wim Mulders, Nimer Ortuño-Gutiérrez, Lutgarde Lynen, Bouke C de Jong, Hans L Rieder |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0233500 |
Similar Items
-
Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
by: Armand Van Deun, et al.
Published: (2021-05-01) -
High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin
by: Mahamadou Bassirou Souleymane, et al.
Published: (2023-08-01) -
Management of falsepositive rifampicin resistant Xpert MTB/RIF – Authors' reply
by: Jean Claude Semuto Ngabonziza, et al.
Published: (2020-10-01) -
Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis
by: Naomee Shareef, et al.
Published: (2023-09-01) -
Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis
by: Qin Zhou, et al.
Published: (2025-01-01)